l-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials

Authors:
  • RSRichard C. Shelton
    Richard C. Shelton
  • JZJohn M. Zajecka
    John M. Zajecka
  • BEBijan Etemad
    Bijan Etemad
  • KRKarl Rickels
    Karl Rickels
  • ACAlisabet Clain
    Alisabet Clain
  • LBLee Baer
    Lee Baer
  • EDElizabeth D. Dalton
    Elizabeth D. Dalton
  • DSDavid Schoenfeld
    David Schoenfeld
  • MPMichael Pencina
    Michael Pencina
  • AMAllison Meisner
    Allison Meisner

Abstract
Patients with major depression who have an insufficient response to selective serotonin reuptake inhibitors (SSRIs) may benefit from the addition of 15 mg/day of l-methylfolate, the only form of folate that crosses the blood-brain barrier. Adding 7.5 mg/day was no more effective than adding placebo, but 15.0 mg/day plus ongoing SSRI treatment produced a 32% response rate, compared to 15% for augmentation with placebo. Side effects in the two groups were comparable in type and frequency. ObjectiveThe authors conducted two multicenter sequential parallel comparison design trials to investigate the effect of l-methylfolate augmentation in the treatment of major depressive disorder in patients who had a partial response or no response to selective serotonin reuptake inhibitors (SSRIs).MethodIn the first trial, 148 outpatients with SSRI-resistant major depressive disorder were enrolled in a 60-day study divided into two 30-day periods. Patients were randomly assigned, in a 2:3:3 ratio, to receive l-methylfolate for 60 days (7.5 mg/day for 30 days followed by 15 mg/day for 30 days), placebo for 30 days followed by l-methylfolate (7.5 mg/day) for 30 days, or placebo for 60 days. SSRI dosages were kept constant throughout the study. In the second trial, with 75 patients, the design was identical to the first, except that the l-methylfolate dosage was 15 mg/day during both 30-day periods.ResultsIn the first trial, no significant difference was observed in outcomes between the treatment groups. In...

This publication has 33 references indexed in Scilit: